FG
REGN icon

Fairman Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Fairman Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$10.5K – 409
2024
Q2 		$10.5K Hold
10
– – 0.01% 167
2024
Q1 		$9.63K Hold
10
– – 0.01% 161
2023
Q4 		$8.78K Buy
+10
New +$8.23K 0.01% 164

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fairman Group's REGN Position: Q3 2024 in Review

Fairman Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 10 shares — an estimated $10.5K sold.

Fairman Group first reported a position in REGN in Q4 2023 and held it in 3 quarters. The position peaked at $10.5K in Q2 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

  • Fairman Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Fairman Group sold 10 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $10.5K.
  • Fairman Group first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Fairman Group's Regeneron Pharmaceuticals position peaked at $10.5K in Q2 2024.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Fairman Group's 13F filing for Q3 2024, filed 22 Oct 2024.